Novo Nordisk (NYSE:NVO) today launched two new diabetes medications in pharmacies across the U.S.
The Danish company’s Ozempic product is a once-weekly GLP-1 receptor agonist designed to boost glycemic control in adults with Type II diabetes. The injection, administered in a pre-filled pen, won FDA approval in December.
Get the full story at our sister site, Drug Delivery Business News.